Startup Boundless Bio recordsdata to go public — San Diego's first life science IPO of 2024

Native life science startup Boundless Bio filed Wednesday to go public — the primary San Diego biotech to take action this yr.

It’s the first preliminary public providing, or IPO, by a neighborhood life science agency previously 4 months, in accordance with business commerce group Biocom California.

After an unprecedented increase in enterprise capital exercise in 2021, the market has slowed significantly within the U.S. with excessive rates of interest and lingering provide chain points. Not too long ago, dealmaking has picked up, however buyers are being extra selective about how they deploy their cash.

Boundless Bio is a clinical-stage oncology firm growing a novel method to dam sure genes from morphing cells into tumors. It’s working by medical trials for its small molecule therapies that focus on extrachromosomal DNA — genetic materials related to sure cancers.

It has been detected in 14 p.c of early-stage cancers and as much as 40 p.c of metastatic cancers, in accordance with the corporate. These “oncogene amplified” tumors have confirmed troublesome to deal with utilizing present therapies.

The corporate — simply off Genesee Avenue and within the heart of San Diego’s biotech cluster — can be aiming its remedy at sufferers whose tumors aren’t benefiting from present approaches, comparable to molecular focused therapies or immunotherapies.

Boundless Bio has a pipeline of three most cancers medication within the works, a diagnostic check to establish sufferers for its drug and a proprietary platform to analyze different potential most cancers DNA targets.

The corporate didn’t disclose in its submitting with the Securities and Alternate Fee the proposed value of its shares or the quantity of inventory it should provide. It should commerce on the Nasdaq World Market underneath the ticker image “BOLD.”

Boundless Bio raised $100 million final yr and was one in every of solely a handful of native corporations to fundraise a spherical of greater than $100 million in 2023. Leaps by Bayer, the funding arm of drug large Bayer, led the funding spherical with RA Capital Administration.

As of Dec. 31, the corporate has raised $253.5 million and has money, money equivalents, and short-term investments of $120.8 million, in accordance with the submitting. Boundless Bio elevated its money movement by about $36 million from 2022 to 2023.

Final yr, the corporate operated with a web lack of about $49.4 million — a roughly $3.5 million enhance from the earlier yr. As of Dec. 31, Boundless Bio had recorded a deficit of $136.1 million.

Boundless Bio plans to make use of the proceeds from its IPO to additional develop its most cancers therapies and to advance its medication by medical trials. It didn’t disclose the timeline it expects the IPO funds to hold it by. The corporate did anticipate to have preliminary medical proof of idea security and antitumor exercise information for its first drug within the second half of 2024.

Regardless that enterprise capital offers have slowed, life science corporations like Boundless that promise medical information inside months — not years — are getting consideration from buyers.

There’s nonetheless lots of capital out there and in consequence, San Diego has seen some attention-grabbing offers in current months, mentioned Jay Lichter, managing associate of native funding agency Avalon Bioventures.

“Biotech IPOs aren’t liquidity occasions — they’re simply financing in a public setting,” he mentioned.

Lichter defined that there are only a few large business life science corporations right here — excluding well being care instrument makers like Thermo Fisher and Illumina — they usually’re not the pharmaceutical giants making medication. Due to this fact, the large return for buyers and the driving force of San Diego’s biotech market comes from mergers and acquisitions. Though San Diego hasn’t recorded many life science IPOs in current months, it has recorded a handful of acquisitions.

For instance, in January Johnson & Johnson purchased San Diego’s Ambrx Biopharma for $2 billion. Two weeks later, French pharma large Sanofi bought Inhibrx, together with a promising drug remedy, for as much as $2.2 billion.

In 2023, the U.S. inventory market noticed 154 IPOs, down 15 p.c from 2022, which had 181 IPOs. That’s a far cry from the document variety of 1,035 IPOs in 2021.

Final yr, many of those public entrants had been within the well being care business, together with San Diego’s personal RayzeBio, which went from a September IPO to a $4.1 billion buyout by Bristol Myers Squibb in December.

Boundless Bio’s IPO is underwritten by Goldman Sachs & Co., Leerink Companions, Piper Sandler and Guggenheim Securities.